SIGA has TREATMENT for ebola -- out-of-control outbreak
The ebola outbreak in Guinea, Sierra Leone, and Liberia, which has already killed 467 people, has been declared an out-of-control outbreak by the CDC and the European Commission.
SIGA has a treatment for ebola (patent application number 20130261087 of 10/03/2013). The SIGA antiviral compounds work in the treatment and prophylaxis of viral infections such as those caused by hemorrhagic fever viruses, which include Arenaviridae (Junin, Machupo, Guanarito, Sabia, Lassa, Tacaribe, Pinchinde, and VSV), Filoviridae (ebola and Marburg viruses), Flaviviridae (yellow fever, omsk hemorrhagic fever and Kyasanur Forest disease viruses), and Bunyaviridae (Rift Valley fever).
In fact, most of these largely untreatable viral diseases present a considerable risk of becoming weapons of bio-terrorism. But as for ebola, a treatment is needed now to save lives.
Therefore, look for the US CDC to finance rush shipments of SIGA's experimental treatment of ebola to the affected region in west Africa (just the way SIGA's smallpox treatment was authorized for use in a patient before FDA approval).
Meanwhile, SIGA is developing a treatment for the much more widespread viral infection that causes dengue fever. This orally bioavailable treatment appears to have a novel mechanism of action against all four serotypes of dengue virus in vitro, and has demonstrated efficacy in animal models.